Pseudomyxoma Peritonei clinical trials at UCSF
1 research study open to eligible people
Pseudomyxoma Peritonei is a rare cancer that starts in the appendix. UCSF is recruiting for a clinical trial that will test a drug called SGN-STNV to see if it is safe for patients with solid tumors. The study will determine what side effects, if any, the drug may cause.
A Study of SGN-STNV in Advanced Solid Tumors
open to eligible people ages 18 years and up
This trial will look at a drug called SGN-STNV to find out whether it is safe for patients with solid tumors. It will study SGN-STNV to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study how well SGN-STNV works to treat solid tumors. The study will have two parts. Part A of the study will find out how much SGN-STNV should be given to patients. Part B will use the dose found in Part A to find out how safe SGN-STNV is and if it works to treat certain types of solid tumors.
San Francisco, California and other locations
Our lead scientists for Pseudomyxoma Peritonei research studies include Pamela Munster.